Pediatric cancer recurrence poses a significant challenge for young patients and their families, particularly in cases involving brain tumors like gliomas.Recent advancements in AI in medicine are shifting the landscape of relapse risk assessment by utilizing novel approaches to predict the likelihood of recurrence more accurately than traditional methods.